Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity (The 'deNUC' Study; TMC114HIV2030)

Trial Profile

Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity (The 'deNUC' Study; TMC114HIV2030)

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Cobicistat/darunavir (Primary) ; Dolutegravir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms deNUC
  • Most Recent Events

    • 27 Oct 2016 Status changed from not yet recruiting to active, no longer recruiting.
    • 23 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top